SQUADRON CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F
WESTMONT, DELAWARE
CIK 0002050709
· CRD 334296
· SEC-registered investment adviser
$398.5M Reported Value Total
SQUADRON CAPITAL MANAGEMENT LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $385,684,763, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $385.7M gross asset value
Hedge Fund: $385.7M
Source: Form ADV filed 2026-06-29
Reported value
$398.5M
Quarter over quarter
-8.5%
Holdings
35
Top-10 concentration
56.6%
Key People
Form ADV owners & control persons
William Fred Blank
PORTFOLIO MANAGER
Matthew Zachary Sesterhenn
HEAD OF RESEARCH
Jared Allan Gandy
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $398.5M |
| Positions | 35 |
| Change in reported value | +23.7% |
| New positions | 17 |
| Exited positions | 16 |
| Position turnover | 64.7% |
| Top-10 concentration | 56.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $398.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
34 | $322.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
30 | $272.9M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $236.0M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KOD KODIAK SCIENCES INC | $39.8M | 9.99% |
| 2 | CCCC C4 THERAPEUTICS INC | $31.0M | 7.79% |
| 3 | COGT COGENT BIOSCIENCES INC | $29.3M | 7.35% |
| 4 | KOD C KODIAK SCIENCES INC | $25.6M | 6.42% |
| 5 | SLN SILENCE THERAPEUTICS PLC | $22.8M | 5.72% |
| 6 | ZNTL ZENTALIS PHARMACEUTICALS INC | $18.9M | 4.75% |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | $17.3M | 4.33% |
| 8 | RLAY RELAY THERAPEUTICS INC | $14.2M | 3.56% |
| 9 | ORIC ORIC PHARMACEUTICALS INC | $13.5M | 3.38% |
| 10 | RLMD RELMADA THERAPEUTICS INC | $13.2M | 3.31% |
| 11 | DFTX DEFINIUM THERAPEUTICS INC | $12.9M | 3.25% |
| 12 | PHVS PHARVARIS N V | $12.7M | 3.18% |
| 13 | ANL ADLAI NORTYE GROUP LTD | $12.2M | 3.07% |
| 14 | VERA VERA THERAPEUTICS INC | $9.8M | 2.47% |
| 15 | IVA INVENTIVA SA | $8.9M | 2.22% |
| 16 | IRON C DISC MEDICINE INC | $8.8M | 2.21% |
| 17 | COGT C COGENT BIOSCIENCES INC | $8.5M | 2.13% |
| 18 | AVTX AVALO THERAPEUTICS INC | $6.9M | 1.73% |
| 19 | ACRS ACLARIS THERAPEUTICS INC | $6.3M | 1.58% |
| 20 | RZLT C REZOLUTE INC | $5.5M | 1.38% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.